Literature DB >> 14723270

Subependymal giant cell astrocytoma with positive tuberin expression--case report.

Sadaharu Tabuchi1, Haruo Takigawa, Akira Oka, Masashi Mizuguchi, Yasushi Horie, Takashi Watanabe.   

Abstract

An 11-year-old male presented with subependymal giant cell astrocytoma (SEGA) without other manifestations of tuberous sclerosis such as facial angiofibroma, epilepsy, or mental retardation. The diagnosis was "possible tuberous sclerosis complex" (TSC). Total resection of the tumor was performed. Immunohistochemical study revealed positive tuberin expression. In general, loss of tuberin is thought to be critical to the TSC phenotype. Our case demonstrated clear expression of tuberin in the SEGA specimen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14723270     DOI: 10.2176/nmc.43.616

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

1.  A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism.

Authors:  Tomotsugu Ichikawa; Akiko Wakisaka; Shigeru Daido; Soichiro Takao; Takashi Tamiya; Isao Date; Shoichi Koizumi; Yo Niida
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

2.  Brain tumor formation in tuberous sclerosis depends on Erk activation.

Authors:  Jaroslaw Jozwiak; Wieslawa Grajkowska; Katarzyna Kotulska; Sergiusz Jozwiak; Wojciech Zalewski; Agnieszka Zajaczkowska; Marcin Roszkowski; Artur Slupianek; Pawel Wlodarski
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

3.  Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.

Authors:  Martine Fohlen; Ines Harzallah; Marc Polivka; Fabienne Giuliano; Linda Pons; Nathalie Streichenberger; Georg Dorfmüller; Renaud Touraine
Journal:  Childs Nerv Syst       Date:  2020-02-26       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.